Mobocertinib

CHEMBL4650319 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

585.7 g/mol

LogP

4.4

Phase

4

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

الوزن الجزيئي

585,7000 g/mol

LogP

4,40

TPSA

114,00 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Non-Small Cell Lung Cancer

آلية العمل

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C=CC(=O)Nc1cc(Nc2ncc(C(=O)OC(C)C)c(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C

InChI

InChI=1S/C32H39N7O4/c1-9-29(40)34-24-16-25(28(42-8)17-27(24)38(6)15-14-37(4)5)35-32-33-18-22(31(41)43-20(2)3)30(36-32)23-19-39(7)26-13-11-10-12-21(23)26/h9-13,16-20H,1,14-15H2,2-8H3,(H,34,40)(H,33,35,36)

Molecular Formula

C32H39N7O4

HBD / HBA

2 / 9

الروابط القابلة للدوران

13

الذرات الثقيلة

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

This tyrosine kinase inhibitor is specifically designed to target a particular mutation in the EGFR gene—exon 20 insertions—that occurs in a subset of non-small cell lung cancer patients who do not respond well to standard EGFR inhibitors. It provides a targeted treatment option for this previously difficult-to-treat lung cancer subgroup.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Mobocertinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650319. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 118607832. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Mobocertinib على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C32H39N7O4

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.